Upgrade to SI Premium - Free Trial

Xtandi Congressional Letter and CFO Change a Modest Negative at Worst for Medivation (MDVN) - UBS

March 29, 2016 8:38 AM
UBS Analyst, Matthew Roden, sees the Medivation (NASDAQ: MDVN) CFO change as a positive and the Congressional letter threatening Xtandi ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA Trader Talk

Next Articles